Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
67.08
+0.05 (+0.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
April 08, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 03, 2024
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
Via
MarketBeat
Topics
ETFs
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
March 28, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024
From
Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via
GlobeNewswire
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
March 11, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
February 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
February 27, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
February 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
February 12, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
February 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
February 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
February 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
February 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
January 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Amended Collaboration and Equity Investment
January 29, 2024
From
Arcus Biosciences
Via
Business Wire
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Courts Find Gilead "Morally Blameworthy" for Withholding HIV Medication
January 23, 2024
January 23, 2024 -- California's Court of Appeals denies Gilead Sciences' request for immunity from liability
Via
24-7 Press Release
Gilead Provides Update on Phase 3 EVOKE-01 Study
January 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.